AstraZeneca diabetes drug granted fast track status for heart...

(Reuters) - AstraZeneca’s diabetes drug, been granted fast track by AstraZeneca diabetes drug U. S. for treatment failure, British drugmaker on Monday. Farxiga, is SGLT2-inhibitor class antidiabetics that cause to expel blood sugar body through urine. Diabetes is often associated a high risk failure. AstraZeneca made strides month towards its goal adding failure to conditions that can be by Farxiga, following positive in a late-stage trial as a ‘wild-card’ by market.

A cutting-edge cancer treatment can also cure certain kinds of heart failure in mice, scientists reported on Wednesday. The treatment is a type of immunotherapy known as CAR-T, which has proved life-changing for some patients with blood cancers. CAR-T relies on engineered white blood cells — T cells — that seek out and destroy malignant cells in the body. In heart failure treatment the new study, published in the journal Nature, the technology was used to target scar tissue that stiffens the heart and prevents it from fully relaxing between beats in heart failure patients. “It is potentially a breakthrough paper,” said Dr. Richard Lee, professor of stem cell and regenerative biology at Harvard who was not involved in the new study. .

New Delhi: Heart failure is common medical condition wherein is an inability pump blood per body’s requirement. If This Treatment Can have we say that capacity is around (ejection fraction) when 100 ml blood reaches is pumped back circulation, then this fraction would come down 30-35 per cent, cannot Congestive Heart Failure pump blood, doesn’t get adequate blood Moreover, diabetes or we tell everything need know about failure along with measures.